Clinical Trial Update: Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation and dose-expansion trial of GSK525762 in combination with androgen deprivation therapy in castration-resistant prostate cancer was termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• GSK525762

Snippet

Sponsor: GlaxoSmithKline | Conditions: Solid Tumours | Phase 1 | Status: TERMINATED | Results posted: 2021-08-26